RxDoctor Payments Data

Chanukya Dahagam

Clinical Cardiac Electrophysiology · Indianapolis, INNPI 1003103953

Payments from drug & device makers

What this record shows

This record is dominated by grants: $17,554 of the $22,202 with a category attached, or 79.1%. Medtronic accounts for 62.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2020 at $17,495 and has fallen 95.3% since, to $830 in 2025.

$22,202in general payments, 2019–2025

Across 143 payments — averaging $155.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$14K
  • Abbott$5K
  • Boston Scientific$2K
  • Biotronik Inc.$397
  • Biosense Webster, Inc.$117
  • AstraZeneca$100
  • plus $329 from 8 others

What the payments were for

  • Grants$17,55479%
  • Food & beverage$4,29819%
  • Education$3502%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,202 in reported general payments places this provider in the 60th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$288,007
Medicare patients
719
Services billed
3,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban520$630,548
XareltoRivaroxaban76$100,878
Dofetilide42$5,030
Metoprolol Succinate448$4,660
Diltiazem 24hr Er (Cd)Diltiazem Hcl94$2,920
Amiodarone Hcl140$2,320
Flecainide Acetate53$1,271
SotalolSotalol Hcl29$760
Pantoprazole Sodium65$728
Verapamil ErVerapamil Hcl16$626
Metoprolol Tartrate67$445
Carvedilol44$378
Warfarin Sodium14$98
Amlodipine Besylate11$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$630,548520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →